Downstream Processing Featured Articles
-
At Ferring Pharmaceuticals, Peptides And Proteins Make Significant Advances
11/15/2013
Dr. Keith James joined Ferring Pharmaceuticals as VP of Therapeutic Innovation in early 2012. In December 2012 he was promoted to president of the Ferring Research Institute and SVP of R&D for Ferring Pharmaceuticals. Prior to joining Ferring, Dr. James spent 29 years working for Pfizer, with significant time spent in discovery research. At the 2013 Oligonucleotide & Peptide Based Therapeutics Congress he will speak on recent progress and future prospects in the peptide and protein therapeutic space. I recently spoke with Dr. James to get an overview of the potential in this market.
-
New Epoch 2 Provides Enhanced User Interface For Spectral Absorbance Detection
7/2/2014
BioTek proudly unveils the new Epoch™ 2 Microplate Spectrophotometer. Epoch 2 is the first reader to combine a large touchscreen and full onboard data analysis software for simplified and efficient operation and reporting of absorbance-based detection workflows.
-
Genetic Immunity Receives GMP Certification For In-House Manufacturing Facility
10/8/2012
Genetic Immunity (OTCBB: PWRV) is pleased to announce the GMP approval of its manufacturing facility. The development of the GMP manufacturing process and the facility was financed from a $4 million grant received from the Hungarian Office for Innovation and Technology.
-
Frost & Sullivan: Biosimilars Market Expected To Soar
2/14/2013
Top representatives from the healthcare industry are confirmed to attend the 2nd Biosimilars Congregation which will take place in London on the 19th and 20th of February 2013. Ranjith Gopinathan, Frost & Sullivan Program Manager for Life Sciences, Europe Practice is set to participate to the event’s Keynote Panel Discussion focusing on challenges and opportunities in the global biosimilars market.
-
Saint-Gobain Introduces Sani-Tech® Ultra
6/27/2012
Saint-Gobain Performance Plastics continues its long tradition of innovation in ultra-pure tubing technology with new Sani-Tech® Ultra. This platinum-cured silicone tubing meets the stringent requirements of demanding biopharmaceutical process applications while delivering improved performance in a number of areas.
-
Brooks’ Single-Use REMP Tubes Support Optimization Of Automated Serum And Plasma Storage
9/12/2012
Brooks Life Science Systems, a division of Brooks Automation, Inc. a leading worldwide provider of automation solutions for compound and biological sample storage and management, announced recently that Karolinska Institute Biobank (KI Biobank) is successfully using Brooks’ REMP single-use heat sealed sample tubes to secure the long-term storage of plasma, serum and urine samples in its automated biorepositories.
-
Next-Generation Kinetex Calculator From Phenomenex Customizes Core-Shell HPLC/UHPLC Method Creation
11/30/2011
Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces the next-generation Kinetex Calculator – an online tool that generates customized, optimized Kinetex methods for HPLC or UHPLC systems.
-
Thermo Fisher Scientific And Immundiagnostik Collaborate To Develop Mass Spectrometry-Based Clinical And Research Tools
10/16/2012
Thermo Fisher Scientific, Inc., the world leader in serving science, and Immundiagnostik AG today announced a collaboration to develop novel mass spectrometry-based assays for qualitative and quantitative analysis of proteins and peptides. The goal is development of commercial assays to be widely applicable in research and routine clinical analysis.
-
Cancer Cell Article Demonstrates First Definitive Evidence For Targeting of Pol I As New Approach To Cancer Therapy
7/10/2012
Cylene Pharmaceuticals today announced that research collaborators at the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia have established, for the first time, that RNA Polymerase I (Pol I) activity is essential for cancer cell survival and that its inhibition selectively activates p53 to kill tumors.
-
GeoVax Awarded $1.9 Million Grant By US Government For HIV/AIDS Vaccine Program
10/1/2012
GeoVax Labs, Inc. (
OTCQB : GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced receipt of a $1.9 million award from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, supporting the development of a clade C version of the Company's current clade B vaccine products.